Tunable and reversible drug control of protein production via a self-excising degron

Nature Chemical Biology

Volumn 11, Issue 9, 2015, Pages 713-720

  Chung, Hokyung K ^a   Jacobs, Conor L ^a   Huo, Yunwen ^a   Yang, Jin ^b   Krumm, Stefanie A ^c   Plemper, Richard K ^c,d   Tsien, Roger Y ^b,e,f   Lin, Michael Z ^a,g  

^a STANFORD UNIVERSITY   (United States)

^b San Diego   (United States)

^c EMORY UNIVERSITY   (United States)

^d GEORGIA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 3; PROTEIN; ASUNAPREVIR; BACTERIAL PROTEIN; CARRIER PROTEIN; HYBRID PROTEIN; ISOQUINOLINE DERIVATIVE; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; PHOTOPROTEIN; PROTEIN BINDING; PROTEINASE INHIBITOR; SULFONAMIDE; VIRUS PROTEIN; YELLOW FLUORESCENT PROTEIN, BACTERIA;

ARTICLE; DNA MODIFICATION; EUKARYOTIC CELL; GENE REPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA VIRUS; SMALL MOLECULE ASSISTED SHUTOFF; YEAST; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HEPACIVIRUS; HUMAN; METABOLISM; MOLECULAR GENETICS; NERVE CELL; PRIMARY CELL CULTURE; PROTEIN DEGRADATION; RAT; SPRAGUE DAWLEY RAT; VERO CELL LINE; VIROLOGY;

HEPATITIS C VIRUS; MAMMALIA; RNA VIRUSES;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL PROTEINS; BINDING SITES; CARRIER PROTEINS; CERCOPITHECUS AETHIOPS; GENE EXPRESSION REGULATION; HEK293 CELLS; HELA CELLS; HEPACIVIRUS; HUMANS; ISOQUINOLINES; LUMINESCENT PROTEINS; MOLECULAR SEQUENCE DATA; NEURONS; PRIMARY CELL CULTURE; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SULFONAMIDES; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84939497376     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1869     Document Type: Article

References (56)

1. Sigoillot, F.D. & King, R.W. Vigilance and validation: keys to success in RNAi screening. ACS Chem. Biol. 6, 47-60 (2011).
2. Vogel, C. & Marcotte, E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227-232 (2012).
3. Wu, L. et al. Variation and genetic control of protein abundance in humans. Nature 499, 79-82 (2013).
4. Battle, A. et al. Genomic variation. Impact of regulatory variation from RNA to protein. Science 347, 664-667 (2015).
5. Huang, C.J. et al. Conditional expression of a myocardium-specific transgene in zebrafish transgenic lines. Dev. Dyn. 233, 1294-1303 (2005).
6. Matsukura, S., Jones, P.A. & Takai, D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res. 31, e77 (2003).
7. Butko, M.T. et al. Fluorescent and photo-oxidizing TimeSTAMP tags track protein fates in light and electron microscopy. Nat. Neurosci. 15, 1742-1751 (2012).
8. Lin, M.Z., Glenn, J.S. & Tsien, R.Y. A drug-controllable tag for visualizing newly synthesized proteins in cells and whole animals. Proc. Natl. Acad. Sci. USA 105, 7744-7749 (2008).
9. Jiang, Y. et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J. Med. Chem. 57, 1753-1769 (2014).
10. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003).
11. McPhee, F. et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob. Agents Chemother. 56, 5387-5396 (2012).
12. Talwani, R., Heil, E.L., Gilliam, B.L. & Temesgen, Z. Simeprevir: a macrocyclic HCV protease inhibitor. Drugs Today (Barc) 49, 769-779 (2013).
13. Brass, V. et al. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc. Natl. Acad. Sci. USA 105, 14545-14550 (2008).
14. Yao, N., Reichert, P., Taremi, S.S., Prosise, W.W. & Weber, P.C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7, 1353-1363 (1999).
15. Yuan, L. et al. A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 921-922, 81-86 (2013).
16. Iizuka, R., Yamagishi-Shirasaki, M. & Funatsu, T. Kinetic study of de novo chromophore maturation of fluorescent proteins. Anal. Biochem. 414, 173-178 (2011).
17. Mnaimneh, S. et al. Exploration of essential gene functions via titratable promoter alleles. Cell 118, 31-44 (2004).
18. Morawska, M. & Ulrich, H.D. An expanded tool kit for the auxin-inducible degron system in budding yeast. Yeast 30, 341-351 (2013).
19. Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat. Methods 6, 917-922 (2009).
20. Su, L.J. et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis. Model. Mech. 3, 194-208 (2010).
21. Garas, M., Dichtl, B. & Keller, W. The role of the putative 3' end processing endonuclease Ysh1p in mRNA and snoRNA synthesis. RNA 14, 2671-2684 (2008).
22. Belle, A., Tanay, A., Bitincka, L., Shamir, R. & O'Shea, E.K. Quantification of protein half-lives in the budding yeast proteome. Proc. Natl. Acad. Sci. USA 103, 13004-13009 (2006).
23. Miest, T.S. & Cattaneo, R. New viruses for cancer therapy: meeting clinical needs. Nat. Rev. Microbiol. 12, 23-34 (2014).
24. Russell, S.J., Peng, K.W. & Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658-670 (2012).
25. Msaouel, P., Opyrchal, M., Domingo Musibay, E. & Galanis, E. Oncolytic measles virus strains as novel anticancer agents. Expert Opin. Biol. Ther. 13, 483-502 (2013).
26. Rima, B.K. & Duprex, W.P. The measles virus replication cycle. Curr. Top. Microbiol. Immunol. 329, 77-102 (2009).
27. Zuniga, A. et al. Attenuated measles virus as a vaccine vector. Vaccine 25, 2974-2983 (2007).
28. Lampson, M.A. & Kapoor, T.M. Targeting protein stability with a small molecule. Cell 126, 827-829 (2006).
29. Banaszynski, L.A., Chen, L.-C., Maynard-Smith, L.A., Ooi, A.G.L. & Wandless, T.J. A rapid, reversible and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995-1004 (2006).
30. Iwamoto, M., Bjorklund, T., Lundberg, C., Kirik, D. & Wandless, T.J. A generalchemical method to regulate protein stability in the mammalian central nervous system. Chem. Biol. 17, 981-988 (2010).
31. Stankunas, K. et al. Conditional protein alleles using knock-in mice and a chemical inducer of dimerization. Mol. Cell 12, 1615-1624 (2003).
32. Bonger, K.M., Chen, L.C., Liu, C.W. & Wandless, T.J. Small-molecule displacement of a cryptic degron causes conditional protein degradation. Nat. Chem. Biol. 7, 531-537 (2011).
33. Tae, H.S. et al. Identification of hydrophobic tags for the degradation of stabilized proteins. ChemBioChem 13, 538-541 (2012).
34. Andresen, M., Schmitz-Salue, R. & Jakobs, S. Short tetracysteine tags to ß-tubulin demonstrate the significance of small labels for live cell imaging. Mol. Biol. Cell 15, 5616-5622 (2004).
35. Chen, M., Cortay, J.C. & Gerlier, D. Measles virus protein interactions in yeast: new findings and caveats. Virus Res. 98, 123-129 (2003).
36. Shu, Y. et al. Plasticity in structural and functional interactions between the phosphoprotein and nucleoprotein of measles virus. J. Biol. Chem. 287, 11951-11967 (2012).
37. Devaux, P. & Cattaneo, R. Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function. J. Virol. 78, 11632-11640 (2004).
38. Huh, W.K. et al. Global analysis of protein localization in budding yeast. Nature 425, 686-691 (2003).
39. Pratt, M.R., Schwartz, E.C. & Muir, T.W. Small-molecule-mediated rescue of protein function by an inducible proteolytic shunt. Proc. Natl. Acad. Sci. USA 104, 11209-11214 (2007).
40. Lin, Y.H. & Pratt, M.R. A dual small-molecule rheostat for precise control of protein concentration in mammalian cells. ChemBioChem 15, 805-809 (2014).
41. Cong, F., Zhang, J., Pao, W., Zhou, P. & Varmus, H. A protein knockdown strategy to study the function of ß-catenin in tumorigenesis. BMC Mol. Biol. 4, 10 (2003).
42. Sakamoto, K.M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98, 8554-8559 (2001).
43. Limenitakis, J. & Soldati-Favre, D. Functional genetics in Apicomplexa: potentials and limits. FEBS Lett. 585, 1579-1588 (2011).
44. Mumberg, D., Muller, R. & Funk, M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene 156, 119-122 (1995).
45. Shimobayashi, M. & Hall, M.N. Making new contacts: the mTOR network in metabolism and signaling crosstalk. Nat. Rev. Mol. Cell Biol. 15, 155-162 (2014).
46. Zhou, P. Determining protein half-lives. Methods Mol. Biol. 284, 67-77 (2004).
47. Shoulders, M.D., Ryno, L.M., Cooley, C.B., Kelly, J.W. & Wiseman, R.L. Broadly applicable methodology for the rapid and dosable small molecule-mediated regulation of transcription factors in human cells. J. Am. Chem. Soc. 135, 8129-8132 (2013).
48. Cattaneo, R., Miest, T., Shashkova, E.V. & Barry, M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 6, 529-540 (2008).
49. Meng, X. et al. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol. Ther. 18, 544-551 (2010).
50. Chen, N. et al. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis and antiviral therapy. Virology 409, 328-337 (2011).
51. Thomas, B.J. & Rothstein, R. Elevated recombination rates in transcriptionally active DNA. Cell 56, 619-630 (1989).
52. Brindley, M.A. et al. A stabilized headless measles virus attachment protein stalk efficiently triggers membrane fusion. J. Virol. 87, 11693-11703 (2013).
53. Buchholz, U.J., Finke, S. & Conzelmann, K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73, 251-259 (1999).
54. Krumm, S.A., Takeda, M. & Plemper, R.K. The measles virus nucleocapsid protein tail domain is dispensable for viral polymerase recruitment and activity. J. Biol. Chem. 288, 29943-29953 (2013).
55. Ono, N. et al. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J. Virol. 75, 4399-4401 (2001).
56. Plemper, R.K., Hammond, A.L., Gerlier, D., Fielding, A.K. & Cattaneo, R. Strength of envelope protein interaction modulates cytopathicity of measles virus. J. Virol. 76, 5051-5061 (2002).